CHRS
Coherus BioSciences, Inc. [CHRS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CHRS Stock Summary
Top 10 Correlated ETFs
CHRS
Top 10 Correlated Stocks
CHRS
In the News
CHRS Financial details
Company Rating
Neutral
Market Cap
248.34M
Income
-236.94M
Revenue
257.24M
Book val./share
-1.73
Cash/share
1.06
Dividend
-
Dividend %
-
Employees
306
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-1.3
Forward P/E
-
PEG
0.33
P/S
1.57
P/B
-2.18
P/C
1.92
P/FCF
-1.27
Quick Ratio
1.45
Current Ratio
1.85
Debt / Equity
-2.46
LT Debt / Equity
-2.45
-
-
EPS (TTM)
-2.55
EPS next Y
-
EPS next Q
-
EPS this Y
-39.9%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-6.3%
Revenue Q/Q
22.74%
EPS Q/Q
73.17%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
77.95%
Inst Trans
0.72%
ROA
-38%
ROE
139%
ROC
-0.54%
Gross Margin
58%
Oper. Margin
-88%
Profit Margin
-106%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.43-8.65
52W High
-74.62%
52W Low
+103.01%
RSI
35
Rel Volume
0.71
Avg Volume
3.49M
Volume
2.49M
Perf Week
-15.76%
Perf Month
-15.06%
Perf Quarter
-23.1%
Perf Half Y
-45.57%
-
-
-
-
Beta
0.514
-
-
Volatility
0.09%, 0.14%
Prev Close
1.51%
Price
2.0301
Change
-5.58%
CHRS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 5.11 | 6.66 | 4.33 | 2.72 | 2.73 | |
| Net income per share | 1.29 | 1.85 | -4.06 | -4.21 | -2.53 | |
| Operating cash flow per share | 0.41 | 2.16 | -0.5 | -3.11 | -1.86 | |
| Free cash flow per share | 0.22 | 2.06 | -0.51 | -3.13 | -1.86 | |
| Cash per share | 2.55 | 7.58 | 5.53 | 2.47 | 1.25 | |
| Book value per share | 1.51 | 3.93 | 1.3 | -1.77 | -2.05 | |
| Tangible book value per share | 1.46 | 3.88 | 1.25 | -1.85 | -2.82 | |
| Share holders equity per share | 1.51 | 3.93 | 1.3 | -1.77 | -2.05 | |
| Interest debt per share | 2.84 | 6 | 5.76 | 6.54 | 5.48 | |
| Market cap | 1.25B | 1.24B | 1.2B | 614.83M | 313.56M | |
| Enterprise value | 1.26B | 1.1B | 1.2B | 1.02B | 691.51M | |
| P/E ratio | 13.97 | 9.39 | -3.93 | -1.88 | -1.32 | |
| Price to sales ratio | 3.52 | 2.61 | 3.69 | 2.91 | 1.22 | |
| POCF ratio | 44.25 | 8.05 | -32.17 | -2.55 | -1.79 | |
| PFCF ratio | 81.16 | 8.44 | -31.1 | -2.53 | -1.79 | |
| P/B Ratio | 11.92 | 4.42 | 12.32 | -4.47 | -1.62 | |
| PTB ratio | 11.92 | 4.42 | 12.32 | -4.47 | -1.62 | |
| EV to sales | 3.53 | 2.32 | 3.66 | 4.84 | 2.69 | |
| Enterprise value over EBITDA | 11.37 | 7.04 | -4.53 | -4.04 | -3.65 | |
| EV to operating cash flow | 44.27 | 7.16 | -31.93 | -4.24 | -3.95 | |
| EV to free cash flow | 81.21 | 7.51 | -30.87 | -4.2 | -3.95 | |
| Earnings yield | 0.07 | 0.11 | -0.25 | -0.53 | -0.76 | |
| Free cash flow yield | 0.01 | 0.12 | -0.03 | -0.4 | -0.56 | |
| Debt to equity | 1.72 | 1.45 | 4.21 | -3.46 | -2.46 | |
| Debt to assets | 0.44 | 0.48 | 0.61 | 0.99 | 0.76 | |
| Net debt to EBITDA | 0.01 | -0.87 | 0.03 | -1.61 | -2 | |
| Current ratio | 3.26 | 9.69 | 8.02 | 7.65 | 1.43 | |
| Interest coverage | 6.12 | 7.39 | -11.49 | -7.91 | -4.77 | |
| Income quality | 0.32 | 1.17 | 0.13 | 0.83 | 0.74 | |
| Dividend Yield | 0.06 | 0.02 | 0 | 0.01 | 0 | |
| Payout ratio | 0.8 | 0.15 | -0.01 | -0.01 | 0 | |
| Sales general and administrative to revenue | 0.37 | 0.28 | 0.49 | 0.89 | 0 | |
| Research and developement to revenue | 0.26 | 0.3 | 1.11 | 0.94 | 0.4 | |
| Intangibles to total assets | 0.01 | 0 | 0.01 | 0.01 | 0.11 | |
| Capex to operating cash flow | -0.45 | -0.05 | 0.03 | 0.01 | 0 | |
| Capex to revenue | -0.04 | -0.01 | 0 | -0.01 | 0 | |
| Capex to depreciation | -3.96 | -2.44 | -0.37 | -0.55 | -0.08 | |
| Stock based compensation to revenue | 0.09 | 0.1 | 0.16 | 0.24 | 0.17 | |
| Graham number | 6.62 | 12.8 | 10.88 | 12.95 | 10.81 | |
| ROIC | 0.35 | 0.22 | -0.54 | -0.83 | -0.67 | |
| Return on tangible assets | 0.22 | 0.16 | -0.45 | -0.69 | -0.43 | |
| Graham Net | 0.11 | 2.02 | -0.34 | -3.69 | -5.08 | |
| Working capital | 259.76M | 708.86M | 554.44M | 362.24M | 143.86M | |
| Tangible asset value | 101.65M | 277.41M | 94.16M | -143.35M | -265.1M | |
| Net current asset value | 71.02M | 229.72M | 51.86M | -201.57M | -347.4M | |
| Invested capital | 1.72 | 1.45 | 4.21 | -3.46 | -2.46 | |
| Average receivables | 70.13M | 149.52M | 140.03M | 116.49M | 185.24M | |
| Average payables | 20.64M | 20.59M | 15.68M | 13.84M | 23.37M | |
| Average inventory | 28.37M | 73.63M | 92.72M | 104.15M | 88.83M | |
| Days sales outstanding | 145.55 | 120.47 | 137.51 | 190.18 | 369.65 | |
| Days payables outstanding | 555.37 | 147.3 | 102.41 | 60.03 | 78.97 | |
| Days of inventory on hand | 1.18K | 893.33 | 591.01 | 599.2 | 140.38 | |
| Receivables turnover | 2.51 | 3.03 | 2.65 | 1.92 | 0.99 | |
| Payables turnover | 0.66 | 2.48 | 3.56 | 6.08 | 4.62 | |
| Inventory turnover | 0.31 | 0.41 | 0.62 | 0.61 | 2.6 | |
| ROE | 0.85 | 0.47 | -3.13 | 2.38 | 1.23 | |
| Capex per share | -0.19 | -0.1 | -0.02 | -0.03 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.58 | 0.41 | 0.67 | 0.76 | 0.82 | |
| Net income per share | -0.85 | -0.94 | -0.49 | -0.41 | -0.71 | |
| Operating cash flow per share | -1.28 | -0.87 | -0.45 | -0.56 | -0.12 | |
| Free cash flow per share | -1.28 | -0.87 | -0.45 | -0.56 | -0.12 | |
| Cash per share | 2.46 | 1.62 | 1.66 | 1.34 | 1.06 | |
| Book value per share | -1.76 | -2.48 | -2 | -1.37 | -1.73 | |
| Tangible book value per share | -1.84 | -2.55 | -2.07 | -1.84 | -2.38 | |
| Share holders equity per share | -1.76 | -2.48 | -2 | -1.37 | -1.73 | |
| Interest debt per share | 6.22 | 6.13 | 5.61 | 4.79 | 4.36 | |
| Market cap | 617.41M | 542.2M | 372.64M | 365.54M | 371.27M | |
| Enterprise value | 1.02B | 997.67M | 778.98M | 763.96M | 749.22M | |
| P/E ratio | -2.33 | -1.81 | -2.17 | -2.31 | -1.17 | |
| Price to sales ratio | 13.61 | 16.72 | 6.35 | 4.9 | 4.06 | |
| POCF ratio | -6.18 | -7.89 | -9.58 | -6.73 | -28.7 | |
| PFCF ratio | -6.17 | -7.87 | -9.55 | -6.73 | -28.62 | |
| P/B Ratio | -4.49 | -2.76 | -2.13 | -2.74 | -1.92 | |
| PTB ratio | -4.49 | -2.76 | -2.13 | -2.74 | -1.92 | |
| EV to sales | 22.6 | 30.76 | 13.27 | 10.25 | 8.19 | |
| Enterprise value over EBITDA | -20.71 | -15.11 | -24.31 | -23.87 | -11.13 | |
| EV to operating cash flow | -10.25 | -14.52 | -20.02 | -14.07 | -57.91 | |
| EV to free cash flow | -10.25 | -14.48 | -19.97 | -14.07 | -57.76 | |
| Earnings yield | -0.11 | -0.14 | -0.12 | -0.11 | -0.21 | |
| Free cash flow yield | -0.16 | -0.13 | -0.1 | -0.15 | -0.03 | |
| Debt to equity | -3.46 | -2.42 | -2.74 | -3.58 | -2.46 | |
| Debt to assets | 0.99 | 1.18 | 1.02 | 0.82 | 0.76 | |
| Net debt to EBITDA | -8.24 | -6.9 | -12.68 | -12.45 | -5.62 | |
| Current ratio | 7.65 | 6.18 | 2.28 | 1.85 | 1.43 | |
| Interest coverage | -5.49 | -6.98 | -3.47 | 3.12 | -6.44 | |
| Income quality | 1.7 | 0.91 | 0.91 | 1.37 | 0.16 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.95 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.64 | 1.05 | 0.4 | 0.34 | 0.28 | |
| Intangibles to total assets | 0.01 | 0.01 | 0.01 | 0.08 | 0.11 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.08 | -0.16 | -0.11 | 0 | -0.03 | |
| Stock based compensation to revenue | 0.26 | 0.38 | 0.17 | 0.13 | 0.12 | |
| Graham number | 5.81 | 7.25 | 4.7 | 3.53 | 5.28 | |
| ROIC | -0.17 | -0.23 | -0.14 | -0.09 | -0.24 | |
| Return on tangible assets | -0.14 | -0.19 | -0.09 | -0.07 | -0.14 | |
| Graham Net | -3.68 | -4.26 | -4.14 | -4 | -4.29 | |
| Working capital | 362.24M | 288.34M | 216.04M | 204.71M | 143.86M | |
| Tangible asset value | -143.35M | -202.38M | -180.57M | -180.12M | -265.1M | |
| Net current asset value | -201.57M | -254.9M | -258.87M | -273.02M | -347.4M | |
| Invested capital | -3.46 | -2.42 | -2.74 | -3.58 | -2.46 | |
| Average receivables | 100.58M | 105.71M | 121.38M | 178.91M | 238.52M | |
| Average payables | 10.72M | 17.38M | 26.25M | 33.19M | 36.16M | |
| Average inventory | 71.39M | 114.77M | 89.24M | 65.39M | 64.69M | |
| Days sales outstanding | 218.22 | 281.51 | 216.6 | 261.32 | 256.18 | |
| Days payables outstanding | 73.04 | 123.91 | 106.05 | 102.08 | 37.02 | |
| Days of inventory on hand | 729.09 | 610.63 | 231.77 | 183.79 | 65.8 | |
| Receivables turnover | 0.41 | 0.32 | 0.42 | 0.34 | 0.35 | |
| Payables turnover | 1.23 | 0.73 | 0.85 | 0.88 | 2.43 | |
| Inventory turnover | 0.12 | 0.15 | 0.39 | 0.49 | 1.37 | |
| ROE | 0.48 | 0.38 | 0.25 | 0.3 | 0.41 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
CHRS Frequently Asked Questions
What is Coherus BioSciences, Inc. stock symbol ?
Coherus BioSciences, Inc. is a US stock , located in Redwood city of Ca and trading under the symbol CHRS
What is Coherus BioSciences, Inc. stock quote today ?
Coherus BioSciences, Inc. stock price is $2.0301 today.
Is Coherus BioSciences, Inc. stock public?
Yes, Coherus BioSciences, Inc. is a publicly traded company.
Company Profile
- Volume Average 3.49M
- Market Capitalization 248.34M
- Employee 306
- CEO Mr. Dennis M. Lanfear
- Headquarters Redwood City,CA,US
- IPO Date 2014-11-06
-
Website
https://www.coherus.com 
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
